ArticleRenal failure2025
Impact of crescents on the immunosuppression treatment of IgA nephropathy.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New Insights on IgA Nephropathy from the Perspective of Active Lesions and Systemic Inflammatory Responses.ImmunoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCrescents are a histopathological feature of the kidney and are associated with poor renal outcomes in patients with IgA nephropathy. The efficacy of immuno-suppressive therapy for IgA nephropathy patients presenting with crescents is still debated.
methodsA total of 1,394 patients were diagnosed with IgA nephropathy with crescents confirmed by renal biopsy between April 2017 and November 2021. The cohort comprised 391 patients receiving immunosuppressive therapy and 391 propensity score-matched patients managed with supportive care. The primary composite outcome included:≥40% eGFR decline from baseline, annual eGFR decline rate >5 mL/min/1.73 m
resultsAmong the 782 individuals, 74 reached the composite outcome, 28 in the immunosuppression group and 46 in the supportive care group. Immunosuppressive therapy was associated with a 39% lower risk of the composite outcome (aHR 0.61; 95% CI, 0.38-0.98). In subgroup analyses of the propensity score-matched cohort, immunosuppressive therapy was associated with a reduced risk of the composite outcome after adjustment for the Oxford classification (M, E, S, T) in IgA nephropathy patients with C1.
conclusionsImmunosuppressive therapy was associated with a 39% lower risk of the composite outcome, demonstrating consistent efficacy in IgA nephropathy with C1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.